Cargando…
Therapies to Slow, Stop, or Reverse Parkinson’s Disease
Our understanding of PD pathophysiology is vastly improved compared to the situation 20 years ago. We have identified the major genetic risks for PD, we now have far more representative animal models of the disease, and we can be inspired by the early successes of others using Antisense Oligonucleot...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311371/ https://www.ncbi.nlm.nih.gov/pubmed/30584162 http://dx.doi.org/10.3233/JPD-181481 |
_version_ | 1783383604465762304 |
---|---|
author | Foltynie, Tom Langston, J. William |
author_facet | Foltynie, Tom Langston, J. William |
author_sort | Foltynie, Tom |
collection | PubMed |
description | Our understanding of PD pathophysiology is vastly improved compared to the situation 20 years ago. We have identified the major genetic risks for PD, we now have far more representative animal models of the disease, and we can be inspired by the early successes of others using Antisense Oligonucleotide and vaccination approaches in other neurodegenerative diseases. We also have a broad range of repurposed drugs showing the first signals of potential efficacy in the translational pipeline which are being driven forward through the various clinical trial stages. We believe we can be optimistic that the next 20 years will be a time for major breakthroughs towards the discovery of therapies that may slow, stop, or reverse PD. |
format | Online Article Text |
id | pubmed-6311371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-63113712019-01-02 Therapies to Slow, Stop, or Reverse Parkinson’s Disease Foltynie, Tom Langston, J. William J Parkinsons Dis Review Our understanding of PD pathophysiology is vastly improved compared to the situation 20 years ago. We have identified the major genetic risks for PD, we now have far more representative animal models of the disease, and we can be inspired by the early successes of others using Antisense Oligonucleotide and vaccination approaches in other neurodegenerative diseases. We also have a broad range of repurposed drugs showing the first signals of potential efficacy in the translational pipeline which are being driven forward through the various clinical trial stages. We believe we can be optimistic that the next 20 years will be a time for major breakthroughs towards the discovery of therapies that may slow, stop, or reverse PD. IOS Press 2018-12-18 /pmc/articles/PMC6311371/ /pubmed/30584162 http://dx.doi.org/10.3233/JPD-181481 Text en © 2018 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Foltynie, Tom Langston, J. William Therapies to Slow, Stop, or Reverse Parkinson’s Disease |
title | Therapies to Slow, Stop, or Reverse Parkinson’s Disease |
title_full | Therapies to Slow, Stop, or Reverse Parkinson’s Disease |
title_fullStr | Therapies to Slow, Stop, or Reverse Parkinson’s Disease |
title_full_unstemmed | Therapies to Slow, Stop, or Reverse Parkinson’s Disease |
title_short | Therapies to Slow, Stop, or Reverse Parkinson’s Disease |
title_sort | therapies to slow, stop, or reverse parkinson’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311371/ https://www.ncbi.nlm.nih.gov/pubmed/30584162 http://dx.doi.org/10.3233/JPD-181481 |
work_keys_str_mv | AT foltynietom therapiestoslowstoporreverseparkinsonsdisease AT langstonjwilliam therapiestoslowstoporreverseparkinsonsdisease |